Changes in Hemophilia Treatment in the Eastern Part of Germany between 2015 and 2021—Data from the Kompetenznetz Hämorrhagische Diathese Ost (KHDO)
The use of EHL and emicizumab has changed hemophilia treatment. About 50% of the sHA patients switched to EHL or emicizumab and almost all sHB patients to EHL. More adults with sHA received prophylaxis and ABR decreased in children.
Authors
- Caspar D. Kühnöl
- Lars Fischer (ORCID: https://orcid.org/0000-0001-5015-222X)
- Ines Halm-Heinrich
- Beate Krammer‐Steiner
- Susanne Holzhauer (ORCID: https://orcid.org/0000-0003-2118-6230)
- Christian Pfrepper (ORCID: https://orcid.org/0000-0002-0485-7402)
- V. Aumann
- Nikola Hagedorn
- Karim Kentouche (ORCID: https://orcid.org/0000-0001-9865-2629)
- Annika Siecke
- Ute Scholz
- Ralf Knöfler
- Kristina Schilling
- Robert Klamroth
- Karolin Trautmann-Grill
Institutions
- University Hospital Leipzig (DE)
- Jena University Hospital (DE)
- University Hospital Magdeburg (DE)
- Klinikum im Friedrichshain (DE)
- University Hospital in Halle (DE)
- University Hospital Carl Gustav Carus (DE)
- Technische Universität Dresden (DE)
- Charité - Universitätsmedizin Berlin (DE)
- Leipzig University (DE)
Publication Details
- Journal
- Hämostaseologie
- Published
- 2025-02-18
- DOI
- https://doi.org/10.1055/a-2499-2912
- Citations
- 1
- Primary Topic
- Hemophilia Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 1.77